BioStar Ventures welcomes entrepreneurs and others to submit an executive summary or PowerPoint to Info@BioStarVentures.com
If there is initial interest upon our review, BioStar Ventures will ask for a complete plan which may lead to the company's management being invited to present to the Managing Directors, Medical Venture Partners, and Advisors. Although the due diligence process can take several months, we try extremely hard to work quickly and keep management apprised of our progress in the diligence process.
Please note that BioStar Ventures does not execute non-disclosure agreements. We also are unable to return copies of executive summaries or business plans.
General Investment Guidelines:
Stage: |
Seed, first or second round of financing. |
Security: |
Typically convertible preferred stock |
Clinical Specialties: |
Cardiovascular, gastroenterology, orthopedics, neurosciences, urological |
Clinical Requirements: |
None. BioStar Ventures will invest in the design stage. |
Other: |
Biomaterials |
Size: |
$250,000 - $3 million in first round |
Board Seat: |
Yes, but not required |
Location: |
Throughout the US |
Technology: |
The product must be based on strongly protected I/P. |
Other: |
BioStar Ventures prefers to invest in those areas where it believes it can serve as a value-add investor in the clinical as well as business efforts of a company. |